CANF
USDCan-Fite Biopharma Ltd Sponsored ADR (Israel)
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$1.070
उच्च
$1.125
कम
$1.050
मात्रा
0.01M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
14.5M
उद्योग
जैव प्रौद्योगिकी
देश
Israel
ट्रेडिंग आँकड़े
औसत मात्रा
0.30M
एक्सचेंज
ASE
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory
Can-Fite Reports 2024 Financial Results and Clinical Update
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।